Artelo Competitors

Stocks . USA . 
Stock . Artelo Biosciences
ARTL Stock  USD 1.29  0.04  3.01%   
Artelo Biosciences competes with GT Biopharma, Protagenic Therapeutics, Psyence Biomedical, Revelation Biosciences, and Lipella Pharmaceuticals; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Artelo Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Artelo Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Artelo Biosciences Correlation with its peers.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

Artelo Biosciences vs Windtree Therapeutics Correlation

Poor diversification

The correlation between Artelo Biosciences and WINT is 0.61 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Artelo Biosciences and WINT in the same portfolio, assuming nothing else is changed.

Moving against Artelo Stock

  0.66GE GE Aerospace Sell-off TrendPairCorr
  0.48AMKBY AP Moeller MaerskPairCorr
  0.45DIS Walt DisneyPairCorr
  0.42BAC Bank of AmericaPairCorr
  0.35RBGPF Reckitt BenckiserPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Artelo Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.071.357.82
Details
Intrinsic
Valuation
LowRealHigh
0.275.4711.94
Details

Artelo Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Artelo Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Artelo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Artelo Biosciences does not affect the price movement of the other competitor.

High positive correlations

WINT
+ 0.92
SPRC
SLRX
+ 0.9
PTIX
LIPO
+ 0.9
PBM
SPRC
+ 0.87
PBM
WINT
+ 0.87
PBM
WINT
+ 0.85
SLXN
  

High negative correlations

SLRX
- 0.12
GTBP

Risk-Adjusted Indicators

There is a big difference between Artelo Stock performing well and Artelo Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Artelo Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GTBP  5.22 (0.87) 0.00 (1.32) 0.00 
 0.00 
 8.33 
(11.96)
 37.01 
PTIX  7.53 (1.44) 0.00  0.82  0.00 
 0.00 
 15.65 
(18.37)
 58.73 
CARM  7.32 (0.22) 0.00  0.43  0.00 
 0.00 
 14.29 
(14.06)
 56.42 
SLRX  6.68 (1.74) 0.00  0.71  0.00 
 0.00 
 16.00 
(16.92)
 61.05 
PBM  6.58 (2.49) 0.00 (1.47) 0.00 
 0.00 
 8.30 
(13.79)
 48.52 
REVB  4.03 (1.48) 0.00 (0.59) 0.00 
 0.00 
 6.84 
(10.16)
 35.57 
LIPO  8.66 (0.90) 0.00 (0.83) 0.00 
 0.00 
 17.65 
(21.74)
 94.73 
SPRC  4.23 (2.14) 0.00 (2.84) 0.00 
 0.00 
 5.00 
(12.50)
 30.69 
SLXN  4.73 (0.90) 0.00 (0.35) 0.00 
 0.00 
 15.09 
(9.15)
 37.24 
WINT  6.26 (2.42) 0.00  31.81  0.00 
 0.00 
 0.00 
(20.00)
 75.00 

Artelo Biosciences Competitive Analysis

The better you understand Artelo Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Artelo Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Artelo Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ARTL GTBP PTIX CARM SLRX PBM REVB LIPO SPRC SLXN
 3.01 
 1.29 
Artelo
 9.62 
 0.47 
GTBP
 4.08 
 0.47 
Protagenic
 2.56 
 0.04 
Carisma
 6.49 
 0.82 
Salarius
 5.07 
 2.81 
Psyence
 2.67 
 1.46 
Revelation
 20.83 
 0.19 
Lipella
 1.64 
 0.60 
Scisparc
 4.24 
 1.58 
Biomotion
Market Volatility
(90 Days Market Risk)
Unstable
Out of control
Out of control
Out of control
Out of control
Dangerous
Somewhat reliable
Extremely Dangerous
Out of control
Very risky
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Strong
High
Risky
Risky
Hazard
Risky
Risky
Low
Low
Risky
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Buy
Not Available
Not Available
Not Available
Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Current Ratio
42.28
2.78
19.47
N/A
8.31
7.95
0.68
N/A
5.59
N/A
Net Asset
4.7 M
4.23 M
1.96 M
30.46 M
3.02 M
7.32 M
6.62 M
2.67 M
10.35 M
2.86 M
Profit Margin
N/A
N/A
N/A
0.15
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(10.11 M)
(13.16 M)
(5.47 M)
(56.83 M)
(5.73 M)
1.03 M
(7.95 M)
(5.01 M)
(6.97 M)
(16.48 M)
Current Valuation
2.16 M
3.96 M
2.22 M
(332.83 K)
2.12 M
3.82 M
(8.75 M)
(736.37 K)
4.04 M
(2.03 M)
Price To Book
0.5
4.58
1.61
114.1
0.73
0.27
0.36
0.57
1.12
0.74
Operating Margin
N/A
N/A
N/A
0.97
N/A
N/A
N/A
-15.64
-5.7
N/A
Retained Earnings
(50.14 M)
(695.23 M)
(36.3 M)
(305.58 M)
(81.92 M)
(56.45 M)
(40.51 M)
(15.34 M)
(74.97 M)
(43.25 M)
Current Asset
99.89 M
N/A
3.75 M
N/A
N/A
327 K
N/A
N/A
N/A
N/A
Beta
1.02
1.25
0.38
3.7
0.32
0.32
-0.13
-0.077
1.25
-0.035
Number Of Employees
6
1
1
46
2
12
8
5
2
11
Shares Outstanding
2.02 M
26.65 M
1.93 M
41.85 M
5.86 M
1.02 M
2.62 M
4.62 M
5.09 M
3.13 M
Cash Flow From Operations
(8.35 M)
(12.9 M)
(4.22 M)
(59.92 M)
(4.53 M)
(3.73 M)
(18.32 M)
(3.95 M)
(5.1 M)
(8.4 M)
Total Debt
104 K
5.9 M
942.76 K
2.48 M
221.87 K
594.37 K
1.91 M
47.6 K
46 K
4.49 M
Return On Equity
-4.36
-3.57
-5.13
-3.63
-1.4
-0.74
-1.19
-2.48
-12.81
-7.71
Return On Asset
-1.36
-1.19
-1.9
0.33
-0.7
-0.34
-0.53
-1.18
-0.99
-0.78
Number Of Shares Shorted
110.41 K
2.69 M
61.71 K
1.29 M
184.64 K
145.42 K
27.31 K
100.09 K
176.03 K
46.2 K
Book Value Per Share
-0.41
0.5
-2.43
-0.021
4.5
39.62
12.27
0.61
15.81
2.23
Current Liabilities
23.67 M
N/A
736 K
N/A
1.97 M
42 K
N/A
N/A
N/A
N/A
Total Asset
4.7 M
4.23 M
1.96 M
30.46 M
3.02 M
7.32 M
6.62 M
2.67 M
10.35 M
2.86 M
Debt To Equity
0.003
0.014
0.035
N/A
0.003
N/A
0.009
N/A
0.007
N/A
Short Ratio
0.45
1.77
0.56
0.06
0.31
0.31
0.17
3.32
0.08
0.8
Target Price
18.0
8.0
4.0
1.0
26.0
N/A
85.0
10.0
N/A
9.0
Shares Owned By Institutions
1.63
3.12
7.09
13.08
5.21
2.95
18.79
1.3
0.62
5.1
Market Capitalization
3.51 M
13.73 M
925.39 K
1.62 M
3.81 M
3.25 M
3.93 M
2.45 M
3.36 M
5.16 M
Price To Earning
16.31
N/A
9.43
N/A
N/A
N/A
8.69
N/A
N/A
N/A
Price To Sales
N/A
N/A
N/A
0.0308
18.12
N/A
2.88
2.19
2.58
N/A
Net Income
(9.83 M)
(13.16 M)
(5.53 M)
(60.48 M)
(5.58 M)
1.01 M
(15.04 M)
(5.02 M)
(7.47 M)
(16.52 M)
Earnings Per Share
-19.5
-3.5
-13.13
0.19
-24.24
-389.98
325.0
-3.33
350.73
349.09
Shares Owned By Insiders
0.47
2.74
3.59
26.56
0.63
4.91
22.82
6.52
29.82
4.6
Revenue
N/A
N/A
N/A
19.63 M
N/A
N/A
N/A
536.36 K
1.31 M
N/A
Working Capital
785 K
(1.67 M)
940.11 K
7.77 M
1.48 M
5.97 M
4.65 M
1.86 M
6.1 M
(1.27 M)
Cash And Equivalents
21.32 M
23.73 M
8.87 M
N/A
22.65 M
281.63 K
3.48 M
N/A
6.88 M
N/A
Cash Per Share
7.51
0.76
0.51
N/A
10.09
0.02
0.15
N/A
2.15
N/A
Gross Profit
N/A
N/A
N/A
25.28 M
(15.84 M)
N/A
90.91 M
(3.42 M)
506 K
N/A
Day Typical Price
1.27
0.47
0.4
0.0402
0.81
2.85
1.49
0.19
0.61
1.61
Accumulation Distribution
5316.72
107264.0
19565.49
4364.61
0.0952
7681.95
9938.93
0.05
8640.74
1900.71
Market Facilitation Index
0.0
N/A
0.0
N/A
0.08
0.0
0.0
0.01
0.0
0.0
Daily Balance Of Power
(0.24)
(1.00)
(0.09)
0.1389
0.625
(0.54)
(0.29)
(5.00)
(0.17)
(0.58)
Period Momentum Indicator
(0.04)
(0.05)
(0.02)
0.001
0.05
(0.15)
(0.04)
(0.05)
(0.01)
(0.07)
Rate Of Daily Change
0.97
0.9
0.96
1.03
1.06
0.95
0.97
0.79
0.98
0.96
Day Median Price
1.27
0.47
0.36
0.0403
0.8
2.87
1.5
0.2
0.62
1.62
Price Action Indicator
0.005
(0.02)
0.1
2.0E-4
0.045
(0.13)
(0.06)
(0.03)
(0.03)
(0.07)
Coefficient Of Variation
(1,699)
(893.46)
(718.19)
(4,007)
(543.26)
(421.65)
(443.31)
(1,728)
(283.44)
(926.65)
Mean Deviation
4.66
5.22
7.53
7.32
6.68
6.58
4.03
8.66
4.23
4.73
Jensen Alpha
(0.39)
(0.87)
(1.44)
(0.22)
(1.74)
(2.49)
(1.48)
(0.90)
(2.14)
(0.90)
Total Risk Alpha
(0.96)
(1.46)
(2.55)
(1.16)
(2.84)
(3.25)
(1.83)
(2.06)
(2.60)
(1.34)
Standard Deviation
6.53
7.28
11.21
10.28
10.43
9.98
5.81
14.14
5.88
6.81
Kurtosis
3.66
2.5
3.88
2.75
7.77
4.43
3.44
10.0
1.37
1.84
Potential Upside
7.3
8.33
15.65
14.29
16.0
8.3
6.84
17.65
5.0
15.09
Treynor Ratio
6.16
(1.32)
0.8181
0.4279
0.7053
(1.47)
(0.59)
(0.83)
(2.84)
(0.35)
Maximum Drawdown
41.63
37.01
58.73
56.42
61.05
48.52
35.57
94.73
30.69
37.24
Variance
42.65
53.0
125.69
105.67
108.86
99.56
33.7
200.02
34.53
46.36
Market Risk Adjusted Performance
6.17
(1.31)
0.8281
0.4379
0.7153
(1.46)
(0.58)
(0.82)
(2.83)
(0.34)
Risk Adjusted Performance
(0.04)
(0.08)
(0.10)
(0.01)
(0.14)
(0.18)
(0.17)
(0.04)
(0.28)
(0.08)
Skewness
0.9008
(1.08)
0.0771
0.6327
(1.12)
(0.45)
(0.90)
2.08
0.1267
0.9681
Information Ratio
(0.07)
(0.12)
(0.15)
(0.03)
(0.19)
(0.25)
(0.24)
(0.06)
(0.37)
(0.12)
Value At Risk
(10.42)
(11.96)
(18.37)
(14.06)
(16.92)
(13.79)
(10.16)
(21.74)
(12.50)
(9.15)

Artelo Biosciences Competition Performance Charts

Five steps to successful analysis of Artelo Biosciences Competition

Artelo Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Artelo Biosciences in relation to its competition. Artelo Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Artelo Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Artelo Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Artelo Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Artelo Biosciences position

In addition to having Artelo Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Funds Thematic Idea Now

Consumer Funds
Consumer Funds Theme
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:
How To Invest In Artelo
Details
Is Artelo Stock a good investment?
Details
What is Artelo Biosciences' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Artelo Biosciences Correlation with its peers.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Artelo Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Understanding that Artelo Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Artelo Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Artelo Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY